337 related articles for article (PubMed ID: 36874011)
1. Prognosis and personalized treatment prediction in lung adenocarcinoma: An
Ma C; Li F; He Z; Zhao S; Yang Y; Gu Z
Front Pharmacol; 2023; 14():1113808. PubMed ID: 36874011
[No Abstract] [Full Text] [Related]
2. A novel defined risk signature of cuproptosis-related long non-coding RNA for predicting prognosis, immune infiltration, and immunotherapy response in lung adenocarcinoma.
Ma C; Li F; Gu Z; Yang Y; Qi Y
Front Pharmacol; 2023; 14():1146840. PubMed ID: 37670938
[No Abstract] [Full Text] [Related]
3. Crosstalk between copper homeostasis and cuproptosis reveals a lncRNA signature to prognosis prediction, immunotherapy personalization, and agent selection for patients with lung adenocarcinoma.
Ma C; Gu Z; Ding W; Li F; Yang Y
Aging (Albany NY); 2023 Nov; 15(22):13504-13541. PubMed ID: 38011277
[TBL] [Abstract][Full Text] [Related]
4. A novel cuproptosis-related signature predicts prognosis and immunotherapy efficacy in lung adenocarcinoma.
Cui Y; Zhang LJ; Xu YJ; Liu MY
Am J Transl Res; 2023; 15(6):3942-3959. PubMed ID: 37434829
[TBL] [Abstract][Full Text] [Related]
5. Deciphering disulfidptosis: Uncovering a lncRNA-based signature for prognostic assessment, personalized immunotherapy, and therapeutic agent selection in lung adenocarcinoma patients.
Ma C; Zhao H; Sun Y; Ding W; Wang H; Li Y; Gu Z
Cell Signal; 2024 May; 117():111105. PubMed ID: 38369264
[TBL] [Abstract][Full Text] [Related]
6. Prediction of prognosis, immune infiltration, and personalized treatment of hepatocellular carcinoma by analysis of cuproptosis-related long noncoding RNAs and verification
Li S; Zhu Z; Lu J; Cao W; Song F; Xiao C; Zhang P; He Z; Weng J; Xu J
Front Oncol; 2023; 13():1159126. PubMed ID: 37746284
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of a novel cuproptosis-related lncRNA signature associated with prognosis and tumor matrix features to predict immunotherapy in soft tissue carcinoma.
Liu B; Pang K; Feng C; Liu Z; Li C; Zhang H; Liu P; Li Z; He S; Tu C
Front Genet; 2022; 13():1063057. PubMed ID: 36568384
[No Abstract] [Full Text] [Related]
8. Significance of cuproptosis-related lncRNA signature in LUAD prognosis and immunotherapy: A machine learning approach.
Yang L; Cui Y; Liang L; Lin J
Thorac Cancer; 2023 Jun; 14(16):1451-1466. PubMed ID: 37076991
[TBL] [Abstract][Full Text] [Related]
9. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
Wang F; Lin H; Su Q; Li C
World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
[TBL] [Abstract][Full Text] [Related]
10. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma.
Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H
Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612
[TBL] [Abstract][Full Text] [Related]
11. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma.
Xu M; Mu J; Wang J; Zhou Q; Wang J
Front Oncol; 2022; 12():961213. PubMed ID: 35965536
[TBL] [Abstract][Full Text] [Related]
12. A cuproptosis-related lncRNAs risk model to predict prognosis and guide immunotherapy for lung adenocarcinoma.
Li Q; Wang T; Zhu J; Zhang A; Wu A; Zhou Y; Shi J
Ann Transl Med; 2023 Mar; 11(5):198. PubMed ID: 37007546
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of a novel cuproptosis-related signature as a prognostic model for lung adenocarcinoma.
Chen Y; Tang L; Huang W; Zhang Y; Abisola FH; Li L
Front Endocrinol (Lausanne); 2022; 13():963220. PubMed ID: 36353226
[TBL] [Abstract][Full Text] [Related]
14. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma.
Ma S; Zhu J; Wang M; Zhu J; Wang W; Xiong Y; Jiang R; Seetharamu N; Abrão FC; Puthamohan VM; Liu L; Jiang T
Transl Lung Cancer Res; 2022 Oct; 11(10):2079-2093. PubMed ID: 36386454
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a prognostic risk signature for lung adenocarcinoma constructed by six ferroptosis, necroptosis, and pyroptosis-related lncRNAs.
Peng L; Ji J; Zhang C; Wu Z; Sun Y; Fan K; Du W; Liu A; Jiao W
J Thorac Dis; 2022 Oct; 14(10):3955-3974. PubMed ID: 36389299
[TBL] [Abstract][Full Text] [Related]
16. Establishment of a prognostic signature for lung adenocarcinoma using cuproptosis-related lncRNAs.
Yalimaimaiti S; Liang X; Zhao H; Dou H; Liu W; Yang Y; Ning L
BMC Bioinformatics; 2023 Mar; 24(1):81. PubMed ID: 36879187
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of a novel cuproptosis-related stemness signature to predict prognosis and immune landscape in lung adenocarcinoma by integrating single-cell and bulk RNA-sequencing.
Yang J; Liu K; Yang L; Ji J; Qin J; Deng H; Wang Z
Front Immunol; 2023; 14():1174762. PubMed ID: 37287976
[TBL] [Abstract][Full Text] [Related]
18. Bioinformatics construction and experimental validation of a cuproptosis-related lncRNA prognostic model in lung adenocarcinoma for immunotherapy response prediction.
Li L; Cai Q; Wu Z; Li X; Zhou W; Lu L; Yi B; Chang R; Zhang H; Cheng Y; Zhang C; Zhang J
Sci Rep; 2023 Feb; 13(1):2455. PubMed ID: 36774446
[TBL] [Abstract][Full Text] [Related]
19. Cuproptosis-related lncRNAs predict the clinical outcome and immune characteristics of hepatocellular carcinoma.
Zhu H; Mao F; Wang K; Feng J; Cheng S
Front Genet; 2022; 13():972212. PubMed ID: 36212138
[TBL] [Abstract][Full Text] [Related]
20. Characterization of cuproptosis-related lncRNA landscape for predicting the prognosis and aiding immunotherapy in lung adenocarcinoma patients.
Sun X; Song J; Lu C; Sun X; Yue H; Bao H; Wang S; Zhong X
Am J Cancer Res; 2023; 13(3):778-801. PubMed ID: 37034212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
